A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)

NCT07743151 | Not Yet Recruiting Phase 1 FDA Drug

• 1 other identifier: 1406-008
• Study Type: interventional
• Target: 400
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this trial is to compare what happens to MK-1406 in the body of healthy participants when it is given as 2-injections and 3-injections. Researchers also want to learn about the safety of MK-1406 and if people tolerate it.

Conditions

Healthy

Outcome Measures

Primary Outcomes (4)

• Part 1: Area Under the Concentration Time Curve From Time 0 to 4 Weeks (AUC0-4w) of MK-1406

  Blood samples will be collected at pre-specified timepoints to determine the AUC0-4w of MK-1406.

  Predose and at designated timepoints up to 4 weeks postdose

• Part 1 and Part 2: Number of Participants Who Experience One or More Adverse Events (AEs)

  An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

  Up to approximately 43 days postdose

• Part 1 and Part 2: Number of Participants Who Experience At Least One Solicited Injection-Site Reaction

  Solicited injection-site reactions include tenderness, pain, redness/erythema, and swelling. Participants will record injection site reactions using a paper diary. The number of participants with solicited injection-site reactions will be reported.

  Up to approximately 7 days postdose

• Part 1 and Part 2: Number of Participants Who Discontinue Study Due to an AE

  An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.

  Up to approximately 43 days postdose

Secondary Outcomes (3)

• Part 1: Maximum Plasma Concentration (Cmax) of MK-1406

  Predose and at designated timepoints up to 4 weeks postdose

• Part 1: Time to Maximum Plasma Concentration (Tmax) of MK-1406

  Predose and at designated timepoints up to 4 weeks postdose

• Part 1: Plasma Concentration of MK-1406 at 4 Weeks (C4w)

  Predose and at designated timepoints up to 4 weeks postdose

Study Arms (2)

MK-1406 3-Injections

EXPERIMENTAL

Participants receive 3 subcutaneous (SQ) injections of MK-1406 on Day 1.

Drug: MK-1406

MK-1406 2-Injections

EXPERIMENTAL

Participants receive 2 SQ injections of MK-1406 on Day 1.

Drug: MK-1406

Interventions

MK-1406 DRUG

Subcutaneous administration

MK-1406 2-Injections; MK-1406 3-Injections

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Is in good health
• Has body mass index (BMI) 18.0 to 32.0 kg/m\^2

You may not qualify if:

• History of clinically significant endocrine, Gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• History of cancer (malignancy)

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Related Links

• Merck Clinical Trials Information

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 29, 2026
• First Posted: August 3, 2026
• Study Start (Estimated): September 15, 2026
• Primary Completion (Estimated): February 5, 2027
• Study Completion (Estimated): February 5, 2027
• Last Updated: August 3, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share